GSK · Pharma and healthcare · one day
GSK (GSK): news on Friday 13 November 2026
News from the 24 hours to Friday morning, 13 November 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage focused on GSK's patent wins against Pfizer and BioNTech, including a wide injunction, plus a settled dispute with Moderna and a rise in the shares. A large Zantac settlement and a restructuring plan added some caution.
What drove it
- vaccine patent wins
- Zantac settlement
- restructuring and valuation
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Sat 7 Nov | +4.5 | 17 |
| Sun 8 Nov | +5.7 | 2 |
| Mon 9 Nov | −3.3 | 3 |
| Tue 10 Nov | +6.3 | 13 |
| Wed 11 Nov | +4.5 | 6 |
| Thu 12 Nov | +4.5 | 12 |
| Fri 13 Nov | +4.2 | 14 |
7 stories · 14 headlines · strongest first
Pharma and healthcare on 13 NovemberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| GSK valuation gap and fair-value commentary +2.54 headlines today · Commentary pieces discuss GSK's valuation relative to rivals, fair value and the Alamar collaboration. | ||
| +5.8 | Valuation commentary suggests shares still have room despite strong rally | |
| +5.0 | New research partnership prompts positive valuation discussion | |
| −1.7 | Discussion of why shares trade at a discount to peers | |
| +0.8 | Generic market analysis with no clear direction | |
| GSK wins UPC injunction against Pfizer and BioNTech +8.73 headlines today · 5 in all, since 12 November · GSK won a broad European injunction in its vaccine patent dispute with Pfizer and BioNTech. | ||
| +10.0 | Patent dispute resolved with wide-reaching injunction in company's favour | |
| +9.2 | Won injunction covering many countries in vaccine litigation | |
| +5.0 | Only partly successful outcome in patent court dispute | |
| Moderna and GSK resolve dispute over vaccine patents +5.72 headlines today · 11 in all, since 7 November · Coverage reports the GSK-Moderna patent truce and its significance for vaccine patent access. | ||
| +5.0 | Licensing arrangement with Moderna seen as valuable for patent position | |
| +4.2 | Moderna coverage notes a settled dispute with GSK | |
| GSK faces $2.2bn Zantac settlement −1.72 headlines today · Pieces report a $2.2bn Zantac settlement and put GSK stock in focus. | ||
| −1.7 | Large litigation settlement, though it ends a long-running legal overhang | |
| −1.7 | Share focus on large settlement over drug claims | |
| GSK shares climb on Thursday +5.01 headline today · GSK shares rose and beat the market. | ||
| +5.0 | Shares rose and beat the wider market | |
| GSK unveils $2.5bn global restructuring +1.71 headline today · A piece reports GSK's $2.5bn global restructuring. | ||
| +1.7 | Big cost-cutting programme announced, with questions over momentum | |
| GSK sets next year's dividend dates +1.71 headline today · GSK published its dividend dates for next year. | ||
| +1.7 | Routine dividend calendar, mildly supportive for income investors | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.